mRNA-1345 ½ÃÀå ±Ô¸ð, ¿¹Ãø, ½Å¾à ÀλçÀÌÆ®(2032³â)
mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032
»óǰÄÚµå : 1462302
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 30 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,875 £Ü 7,053,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,500 £Ü 9,404,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 9,750 £Ü 14,107,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾àÁ¦ ¿ä¾à

mRNA-1345 ¹é½ÅÀº ¸Þ½ÅÀú RNA(mRNA) ¹é½ÅÀÔ´Ï´Ù. ÀÌ mRNA´Â ¸ðµÎ ½ÇÇè½Ç¿¡¼­ ¸¸µé¾îÁ® ü³»¿¡¼­ ÀÛÀº ´Ü¹éÁú Á¶°¢À» ¸¸µéµµ·Ï Áö½ÃÇϸç, ModernaÀÇ mRNA-1345 RSV ¹é½Å Èĺ¸¹°ÁúÀº ÇÁ¸®Ç»Àü F ´ç´Ü¹éÁúÀ» ¾ÏȣȭÇÏ¿© ¿ì¼öÇÑ ÁßÈ­Ç×ü ¹ÝÀÀÀ» À¯µµÇÕ´Ï´Ù.

ÀÌ °æ¿ì ¹é½Å Èĺ¸¿¡´Â RSV ´ç´Ü¹éÁú FÀÇ mRNA Äڵ尡 Æ÷ÇԵǾî ÀÖÀ¸¸ç, ÀÌ ´Ü¹éÁúÀº RSV °¨¿°À» ÀÏÀ¸Å°Áö ¾ÊÁö¸¸ ¹ÙÀÌ·¯½º°¡ ¹ß»ýÇßÀ» ¶§ ½ÅüÀÇ ¸é¿ª ü°è°¡ ¹ÙÀÌ·¯½º¸¦ ÀνÄÇÏ°í ½º½º·Î¸¦ º¸È£Çϵµ·Ï µµ¿ÍÁÝ´Ï´Ù. µû¶ó¼­ ÀÌ ÀÓ»ó½ÃÇè¿ë ¹é½ÅÀ» Á¢Á¾Çصµ RSV¿¡ °¨¿°µÇÁö ¾ÊÀ¸¸ç, mRNA-1345RSV ¹é½Å Èĺ¸¹°ÁúÀº ÀþÀºÀÌ¿Í ³ëÀÎ(65¼¼ ÀÌ»ó)ÀÇ È£Èí±â ÁúȯÀÇ ÁÖ¿ä ¿øÀÎÀÎ RSV·Î ÀÎÇÑ Áúº´À» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. mRNA-1345´Â ÇöÀç ³ëÀÎÀ» ´ë»óÀ¸·Î ÇÑ 3»ó ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̸ç, RSV´Â ¼Ò¾Æ¿¡°Ôµµ Å« ºÎ´ãÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ¼Ò¾Æ¸¦ ´ë»óÀ¸·Î ÇÑ 1»ó ÀÓ»ó½ÃÇèµµ ÁøÇà ÁßÀÔ´Ï´Ù.

RSV ÇÁ·Î±×·¥Àº 60¼¼ ÀÌ»ó ¼ºÀÎÀ» ´ë»óÀ¸·Î ÇÑ È£Èí±â¼¼Æ÷À¶ÇÕ¹ÙÀÌ·¯½º(RSV) ¹é½Å Èĺ¸ÀÎ mRNA-1345¿¡ ´ëÇÑ ÁÖ¿ä ÀÓ»ó 3»ó ½ÃÇèÀÇ ½ÃÀÛÀ» ½ÂÀÎÇß½À´Ï´Ù. ±× °á°ú, ÀÌ ¹é½ÅÀÌ ¼±ÅÃµÈ ¿ë·®¿¡¼­ °í·ÉÀÚ¿¡¼­ Çã¿ë °¡´ÉÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °¡Áö°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ ½ÃÇèÀº ConquerRSV·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

ÁÖ¿ä 7 ½ÃÀå(¹Ì±¹¡¤µ¶ÀÏ¡¤ÇÁ¶û½º¡¤ÀÌÅ»¸®¾Æ¡¤½ºÆäÀΡ¤¿µ±¹¡¤ÀϺ»)ÀÇ RSV¿ë mRNA-1345¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ÀÛ¿ë±â¼­, ¿ë¹ý°ú ¿ë·®, ¿¬±¸°³¹ß Ȱµ¿¿¡ °üÇÑ ÀλçÀÌÆ®, ¸ÅÃâÀÇ ¿¹Ãø µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸®Æ÷Æ®ÀÇ ¼­·Ð

Á¦2Àå RSV¿¡¼­ÀÇ mRNA-1345 °³¿ä

Á¦3Àå °æÀï ±¸µµ(Ãâ½Ã Ä¡·á¹ý)

Á¦4Àå °æÀï ±¸µµ(Èı⠽ÅÄ¡·á¹ý)

Á¦5Àå mRNA-1345 ½ÃÀå Æò°¡

Á¦6Àå SWOT ºÐ¼®

Á¦7Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦8Àå ºÎ·Ï

Á¦9Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦10Àå ¸éÃ¥»çÇ×

Á¦11Àå DelveInsight ¼Ò°³

Á¦12Àå ¸®Æ÷Æ® ±¸ÀÔ ¿É¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

"mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the mRNA-1345 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1345 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response.

In this case, the vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body's immune system recognize and protect itself if it encounters the virus. Therefore, one cannot become infected with RSV by receiving the investigational vaccine. The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+). Currently, the drug is in Phase III for older adults. mRNA-1345 is also ongoing in a Phase I trial in pediatric populations; RSV is also a large burden in the pediatric population.

RSV program has endorsed the start of the Phase III portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase II data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.

Scope of the Report:

The report provides insights into:

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

mRNA-1345 Analytical Perspective by DelveInsight

This report provides a detailed market assessment of mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

The report provides the clinical trials information of mRNA-1345 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

Key Questions:

Table of Contents

1. Report Introduction

2. mRNA-1345 Overview in RSV

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. mRNA-1345 Market Assessment

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â